Trademarkia Logo

Canada

C$
Trademark Search in Canada
EARLI

View On IC.GC.CA

EARLI
REGISTERED

on 12 Dec 2022

Last Applicant/ Owned by

EARLI INC.

801 California StreetMountain View, CA 94041

US

Serial Number

1938151 filed on 27th Dec 2018

Registration Number

TMA1155802 registered on 12th Dec 2022

Registration expiry Date

12th Dec 2032

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

EARLI

Trademark usage description

biological assays, recombinant nucleic acid vectors, recombinant viral vectors, transfection agents, reagents, and nucleotides for clinical or medical Read More

Classification Information

Class [001]
Biological assays, recombinant nucleic acid vectors, recombinant viral vectors, transfection agents, reagents, and nucleotides for clinical or medical laboratory, scientific, research or therapeutic purposes, namely, biological tissue specimens for use in scientific and clinical research; diagnostic or screening assays or therapeutic agents, reagents, enzymes, and nucleotides for clinical or medical laboratory, scientific, research, diagnostic or treatment purposes, namely, diagnostic and therapeutic reagents for medical and scientific use; biological reagents for medical and genetic research, diagnostic or treatment use namely, diagnostic reagents for medical-scientific research use, chemical reagents and diagnostic or therapeutic preparations for clinical or medical laboratory use, namely, diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology

Classification kind code

11

Class [005]
Pharmaceutical and veterinary preparations and products for the prevention, detection, localization and treatment of diseases or pathogens or toxic substances in humans and animals, namely, pharmaceutical preparations for the prevention, diagnosis and treatment of cancer; pharmaceutical products for the delivery of other pharmaceutical products into human and animal bodies, namely, drug delivery agents serving as coatings for nucleic acids that facilitate the delivery of pharmaceutical preparations; clinical diagnostic or therapeutic reagents and clinical diagnostic kits comprised of clinical diagnostic or therapeutic reagents, namely, clinical reagents for the detection, localization and treatment of cancer; medical diagnostic or therapeutic reagents and medical diagnostic or therapeutic kits comprised of medical diagnostic or therapeutic reagents, namely, diagnostic and therapeutic reagents for medical diagnostic and therapeutic use; reagents for medical use and medical diagnostics or therapeutics or screening kits comprised of reagents for medical diagnostics and screening use or therapeutics, namely, diagnostic and therapeutic reagents for clinical and laboratory use; reagents for use in diagnostic testing for medical and medical diagnostic purposes; reagents for use in therapeutics for medical purposes, namely, blood grouping reagents for medical therapeutic purpose, reagent paper for medical therapeutic purposes, and clinical diagnostic reagents; diagnostic and therapeutic preparations for medical purposes, namely, clinical diagnostic and therapeutic reagents, clinical diagnostic and therapeutic compounds, diagnostic and therapeutic biomarker reagents for medical purposes, diagnostic and therapeutic chemical reagents for medical purposes, diagnostic and therapeutic reagents for clinical laboratory use, and diagnostic and therapeutic reagents for medical diagnostic use; assays, reagents, enzymes, and nucleotides for medical or clinical diagnostics or screening or therapeutics purposes, namely, medical diagnostic reagents and assays for testing and therapeutic treatment of body fluids and tissues; biological assays, recombinant nucleic acid vectors, recombinant viral vectors, transfection agents, reagents, and nucleotides for clinical or medical laboratory, scientific, research or therapeutic purposes, namely, biological tissue cultures for medical and clinical purposes; biological reagents for medical and genetic research, diagnostic or treatment use namely, diagnostic reagents for medical and clinical use

Classification kind code

11

Class [035]
Advertising, marketing, promotional and business

Comment text

CIPO Classification Code

Classification kind code

Nice

Class [044]
Genetic testing and reporting for medical purposes; medical testing for screening, detection, diagnosis, localization or therapeutic application; medical diagnostic testing, monitoring and reporting services; providing medical information regarding diseases, pathogens and toxic substances via a website; healthcare services provided by medical clinics and medical providers or pharmacies; providing healthcare information regarding disease status; medical services for the diagnosis, localization and treatment of diseases or pathogens or toxic substances in humans and animals, namely, medical testing and treatment for diagnostic or treatment purposes; medical analysis services for the diagnosis, localization and treatment of diseases or pathogens or toxic substances in humans and animals, namely, medical care and analysis services relating to patient health status and treatment; providing information in the fields of health, diseases, disease detection, diagnosis, localization, and treatment, namely, medical care and analysis services relating to patient treatment via a computer network

Classification kind code

11

Mark Details

Serial Number

1938151

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 191
on 7th Dec 2022		Registration Fee Notice Sent
Submitted for opposition 190
on 7th Dec 2022		Registration Pending
Submitted for opposition 42
on 14th Sept 2022		Advertised
Submitted for opposition 26
on 18th Aug 2022		Approved
Submitted for opposition 27
on 18th Aug 2022		Approval Notice Sent
Submitted for opposition 22
on 10th Feb 2022		Search Recorded
Submitted for opposition 20
on 10th Feb 2022		Examiner's First Report
Submitted for opposition 31
on 3rd Jan 2019		Formalized
Submitted for opposition 1
on 28th Dec 2018		Created
Submitted for opposition 30
on 27th Dec 2018		Filed